drugset / Trial / NCT04457310
A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia
Phase 2
Completed
112 enrolled
Yale University
Cerevel Therapeutics, LLC · collabColumbia University · collabNational Institute of Mental Health (NIMH) · collabState University of New York Stony Brook · collabUniversity of Pennsylvania · collab
RandomizedCrossoverTriple-blindBasic science
Summary
This study will test whether CVL-562 (PF-06412562), a dopamine 1 partial agonist novel compound, affects working memory neural circuits in patients with early episode schizophrenia. The overall aim is to establish neuroimaging biomarkers of the Dopamine Receptor 1/Dopamine Receptor 5 Family (D1R/D5R) target engagement to accelerate development of D1R/D5R agonists in humans to treat cognitive impairments that underlie functional disability in schizophrenia, a key unaddressed clinical and public health concern.
Timeline
- Start
- 2021-03-02
- Primary completion
- 2024-03-22
- Completion
- 2024-03-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CVL-562 | Unknown | 1 mg | Oral |
| Subject | CVL-562 | Unknown | 4 mg | Oral |
| Subject | CVL-562 | Unknown | 15 mg | Oral |
| Subject | CVL-562 | Unknown | 25 mg | Oral |